Table 2.
Characteristics of treated migraine attacks (ITT population).
| Characteristic | Lasmiditan 100 mg n = 8782 | Lasmiditan 200 mg n = 8513 | All treated migraine attacks n = 17295 |
|---|---|---|---|
| Time to dosing from migraine pain start, mean (SD), h | 1.2 (2.4) | 1.3 (2.8) | 1.2 (2.6) |
| Baseline migraine severity, n (%) | |||
| Severe | 2872 (32.7) | 2846 (33.4) | 5718 (33.1) |
| Moderate | 5762 (65.6) | 5546 (65.1) | 11308 (65.4) |
| Mild | 141 (1.6) | 115 (1.4) | 256 (1.5) |
| None | 7 (0.1) | 6 (0.1) | 13 (0.1) |
| Baseline symptoms, n (%) | |||
| Nausea | 3527 (40.2) | 3188 (37.4) | 6715 (38.8) |
| Phonophobia | 5609 (63.9) | 4988 (58.6) | 10597 (61.3) |
| Photophobia | 6741 (76.8) | 6322 (74.3) | 13063 (75.5) |
| Vomiting | 275 (3.1) | 302 (3.5) | 577 (3.3) |
| None | 792 (9.0) | 962 (11.3) | 1754 (10.1) |
| Baseline MBS, n | 7987 | 7550 | 15537 |
| Nausea, n (%) | 1710 (21.4) | 1683 (22.3) | 3393 (21.8) |
| Phonophobia, n (%) | 1970 (24.7) | 1726 (22.9) | 3696 (23.8) |
| Photophobia, n (%) | 4307 (53.9) | 4141 (54.9) | 8448 (54.4) |
| Other medications taken to treat migraine, n (%) | |||
| Yes, before 2-h assessment | 274 (3.1) | 293 (3.4) | 567 (3.3) |
| Yes, after 2-h assessment | 841 (9.6) | 584 (6.9) | 1425 (8.2) |
| Number of attacks treated with a second dose, n (%) | 3627 (41.3) | 2776 (32.6) | 6403 (37.0) |
| Number of attacks treated with second dose for rescue, n (%) | 3317 (91.5) | 2476 (89.2) | 5793 (90.5) |
| Number of attacks pain free at 2 ha,b, n (%) | 2298 (26.9) | 2665 (32.4) | 4963 (29.6) |
| Number of attacks treated with second dose for recurrence, n (%) | 152 (6.6) | 150 (5.6) | 302 (6.1) |
| Total number of treated migraine attacks during the entire study, mean (SD)c | 9.3 (9.4) | 8.0 (9.0) | 9.0 (9.2) |
| Number of doses taken per treated migraine attack, mean (SD) | 1.4 (0.5) | 1.3 (0.5) | 1.4 (0.5) |
ITT: intent-to-treat; MBS: most bothersome symptom; SD: standard deviation.
Pain freedom is defined as a reduction in pain severity from mild, moderate, or severe at baseline to none at 2 hours post-dose. Patients were assumed to not have achieved pain freedom at 2 hours if they did not have an associated pain severity rating at the 2-hour time point, took rescue medication within the first 2 hours, or used alternative medication prior to the study drug to treat the migraine attack.
Percentages calculated using the number of treated migraine attacks with mild, moderate, or severe headache pain at baseline as denominator: n = 8532 for lasmiditan 100 mg; n = 8232 for lasmiditan 200 mg; n = 16,764 overall.
Percentages calculated using the number of patients with treated migraine attacks that met the ITT criteria as denominator: n = 941 for lasmiditan 100 mg; n = 990 for lasmiditan 200 mg; n = 1931 overall.